Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px
Document › Details

Genedata AG. (11/17/15). "Press Release: Kymab Implements Genedata Biologics for High-throughput Antibody Discovery". Basel.

Organisations Organisation Genedata AG
  Organisation 2 Kymab Group Ltd.
Products Product Genedata Biologics™ software
  Product 2 Kymouse™ technology
Index term Index term Kymab–Genedata: bioinformatics, 201511– license to Genedata Biologics for HT antibody discovery w Kymouse technology
Person Person Pfannes, Othmar (Genedata 200406 CEO)
     


Genedata Biologics™ integrated workflow platform used to increase automation of Kymab’s transgenic mice-based discovery platforms


Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Kymab Ltd. has licensed Genedata Biologics™ for use in their proprietary antibody discovery programs. The platform will support biopharma R&D operations from early B-cell and hybridoma screening, to antibody engineering, expression, purification, and analytics.

“Genedata Biologics is the leading workflow platform for high-throughput antibody discovery. Having access to this platform is expected to enhance Kymab’s capabilities across all our research programs,” said Glenn A. Friedrich, PhD, Chief Operating Officer at Kymab Ltd. “Thanks to Genedata’s flexible business model, we are able to take advantage of Genedata’s unique technology under terms that work well for a company of our size.”

Kymab uses Genedata Biologics for their screening platform to deeply mine the proprietary Kymouse™ antibody repertoire and to identify candidate-quality molecules with exceptionally broad diversity and the quality of fully human antibodies.

“Genedata Biologics makes the antibody discovery and optimization process more efficient. The platform’s open architecture allows us to flexibly configure the system to work with Kymab’s proprietary workflows and technologies, including our transgenic mouse platform,” said David Melvin, PhD, Director of Informatics at Kymab. “We are building our screening, expression, purification, and analytics workflows on the Genedata Biologics platform, which we believe will lead to an increase in throughput and automation.”

“We are delighted that Kymab, a leader in the development of transgenic mouse platforms, is now also taking advantage of the Genedata Biologics platform to further their antibody discovery programs. We see a rapidly growing number of smaller, highly innovative biotech companies like Kymab, who require an integrated workflow platform to manage and streamline their increasingly complex antibody discovery processes,” said Dr. Othmar Pfannes, Chief Executive Officer of Genedata. “We look forward to continue to partner with the best biopharma R&D organizations worldwide.”

In the four short years since its first release in 2011, Genedata Biologics has been rapidly adopted by almost half of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.


About Genedata

Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
www.genedata.com


Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

   
Record changed: 2017-04-02

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Genedata (Group)


To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px